Enriching Cancer Pharmacology with Drugs of Marine Origin.
Marine natural products have proven, over the last half-century, to be effective biological modulators. These molecules have revealed new targets for cancer therapy as well as dissimilar modes of action within typical classes of drugs. In this scenario, innovation from marine-based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first-in-class drugs. Herein, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment - cyrabine (Cytosar-U®), trabectedin (Yondelis®), eribulin (Halaven®), brentuximab vedotin (Adcetris®) and plitidepsin (Aplidin®) - plus those in late clinical trial phases - lurbinectedin, plinabulin, marizomib and plocabulin -, the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy.